Search glutathione dosage and you land in a table. One clinic publishes a schedule. The next publishes a different one, sometimes at twice the size. Each figure is real in the sense that a clinic somewhere follows it, and none of them comes from a drug label, because the United States has no approved glutathione injection to take a label from.
That absence changes the question. We set the numbers clinics quote beside the numbers human studies used, and we name the page each one came from.
The one-sentence answer: the United States has no FDA-approved glutathione product, so no federal dose exists, and the human studies behind the published numbers used 1,400 milligrams by intravenous push three times a week for four weeks, or 250 to 500 milligrams a day by mouth.
Glutathione Dosage: What the Federal Record States
The CDC keeps a page on the 2026 illnesses tied to injected glutathione, and one line on it carries the weight: “There are no FDA-approved glutathione products in the United States” (CDC, reviewed September 15, 2026).
Read that sentence as a dosing fact. An approved drug arrives with a label that states a dose, a reaction list and a manufacturer who answers for both. Glutathione arrives as a dietary supplement for the oral market, or as a compounded injection mixed by a pharmacy. In the second case the dose belongs to the pharmacy’s protocol sheet.
A protocol sheet can be careful. It can also be a number copied from another clinic’s website. Nothing in the federal record separates the two for you, which is why the trial record matters more here than it does for a labeled drug.
Glutathione Dosage in the Human Trials
Four published studies carry most of the human dosing evidence, and they split by route.
The intravenous study is the one clinics quote. Hauser and colleagues randomized 21 patients with Parkinson’s disease to 1,400 milligrams of glutathione or placebo, diluted in 10 milliliters of normal saline, given by intravenous push over 10 minutes on Monday, Wednesday and Friday for four weeks. Their own description of how they picked the number is the part worth memorizing: “This regimen was chosen because of its anecdotal use in clinical practice” (Mov Disord, May 15, 2009).
The result was tolerability, not benefit. Glutathione was well tolerated, with no withdrawals for adverse events in either group, and no significant difference in Unified Parkinson’s Disease Rating Scale changes. Over the four weeks of dosing, the glutathione group improved by a mean of 2.8 units more than placebo, at P = 0.32. Over the following eight weeks it worsened by 3.5 units more, at P = 0.54. The authors called the possibility of a mild symptomatic effect something for a larger study to test.
Read the sequence plainly: a dose used in clinics went into a trial, the trial found no significant difference, and the number stayed in circulation anyway.
The oral studies used much smaller numbers. Arjinpathana and Asawanonda gave 60 healthy medical students 500 milligrams a day in two divided doses, or placebo, for four weeks. Melanin index fell at all six measured sites in the glutathione group and beat placebo at two of them: the right side of the face at p = 0.021 and the sun-exposed left forearm at p = 0.036. Both arms tolerated the capsules well, and the authors closed with a caution that has not been answered since: “long-term safety has not been established” (J Dermatolog Treat, April 2012).
Weschawalit and colleagues ran 60 women for 12 weeks at 250 milligrams a day of reduced glutathione, 250 milligrams a day of oxidized glutathione, or placebo. Their reason for the 250 is worth a second look. The paper says the dose was “a dosage allowed by the Thai and Taiwanese Food and Drug Administrations” (Clin Cosmet Investig Dermatol, April 27, 2017). That is a supplement allowance set by food regulators, carried into a skin trial. It is not a therapeutic dose endorsed by a drug regulator.
Put the verified numbers in one place. Oral evidence sits at 250 to 500 milligrams a day for 4 to 12 weeks. Intravenous evidence sits at 1,400 milligrams three times a week for four weeks, in 21 patients, with a negative primary result. No controlled trial in this record compared one glutathione dose with another, so the clinic schedules that differ from these numbers have no dose-finding work behind them.
The Nebulized Dose That Narrowed Airways
Route does more than change the number. It can change the direction of the effect.
Marrades and colleagues gave eight patients with mild asthma 600 milligrams of glutathione in 4 milliliters of saline by nebulizer, or a matching placebo, in a randomized, double-blind, crossover design. The glutathione solution produced major airway narrowing: FEV1 fell 19 percent against 1 percent on placebo, and total pulmonary resistance rose 61 percent against 17 percent. Four patients coughed and three became breathless. The FEV1 difference reached p = 0.03. Nebulized salbutamol given beforehand blocked the reaction, and the authors attributed it to sulfite formation (Am J Respir Crit Care Med, August 1997).
An antioxidant that narrows an airway in eight people is not a dosing curiosity. It is the reason route belongs in the same sentence as dose.
What the Injectable Dose Carries Besides the Molecule
The serious harm in the federal file came through the powder, and the numbers make that clear.
On January 9, 2019, seven patients at an outpatient clinic received 7 milliliters of compounded L-glutathione at 200 milligrams per milliliter, which is 1,400 milligrams each. Within minutes they reported nausea, vomiting, lightheadedness, chills, body aches and sneezing. One developed low blood pressure and difficulty breathing and was transferred to a hospital. A separate report described a patient who received 12 milliliters, or 2,400 milligrams, and developed sudden chills, fever and shaking before admission for a possible bloodstream infection. FDA’s testing found excessive bacterial endotoxin in the powder, with some results as high as five times the appropriate limit (FDA, June 7, 2019).
The 2026 file repeats the pattern with a different supplier. As of August 27, 2026, FDA reported at least 30 patients with adverse events after intravenous glutathione, compounded by different pharmacies that all bought glutathione, lot 229536, from Medisca. The material was labeled dietary supplement grade (FDA, August 27, 2026).
CDC adds that at least three Texas pharmacies recalled compounded injectable glutathione over high endotoxin levels, and it tells clinics to confirm with the pharmacy that the ingredient was intended for injection. The agency also asks providers to report patients who develop fever, chills, muscle pain, nausea, vomiting, low blood pressure or a fast heart rate during or after a dose.
We keep the full record of that cluster, the recalls and the state count on our glutathione side effects page. The dosing lesson is narrower: the milligram count in the syringe did not decide who got sick. The grade of the powder did.
Where the Dose Numbers Come From: FDA’s Own Advisers
FDA has looked at this molecule directly. On June 8, 2022, its Pharmacy Compounding Advisory Committee took up glutathione as a candidate for the list of bulk substances that pharmacies may use under section 503A, with uses including skin lightening, asthma, Parkinson’s disease and diabetes.
FDA proposed that glutathione not be included. The committee went the other way, voting 8 to 5 with one abstention in favor of adding it. Members who voted no cited “a lack of scientific evidence establishing effectiveness of compounded formulations containing glutathione for the conditions evaluated,” and one member noted that glutathione has been used for a wide range of indications “without clear evidence of effectiveness despite well-established alternate therapies” (FDA, final summary minutes approved August 19, 2022).
That vote was about whether pharmacies may buy the bulk powder. It was not about a dose, and a favorable vote would not have created one. A substance can be legally available to compound and still lack a dose that any trial has validated.
Glutathione Dosage: Questions Worth Asking at the Counter
- What grade is the glutathione, who manufactured it, and was that material intended for injection?
- Which published trial does your protocol come from, and what did that trial find?
- Who supervises the injection, and what is the plan if a reaction starts during the infusion?
- Is the dose written on your consent form traceable to a study, or to a supplier’s suggested protocol?
Our directory lists clinics by city. We do not screen them, so check each license and put these questions to the clinic directly.
Frequently asked questions
Is there an FDA-approved glutathione dose?
No. CDC states that there are no FDA-approved glutathione products in the United States, so there is no label dose for an injection. Oral glutathione sells as a dietary supplement, which is a different regulatory category from a prescription drug.
How much glutathione did the Parkinson’s trial use?
Hauser and colleagues gave 1,400 milligrams in 10 milliliters of saline by intravenous push over 10 minutes, three times a week for four weeks, to 21 patients. The dose was chosen because clinics already used it, and the trial found no significant difference from placebo on motor scores.
What glutathione dose did the skin trials use?
Two randomized trials used oral doses. One gave 500 milligrams a day in two divided doses for four weeks to 60 medical students. The other gave 250 milligrams a day for 12 weeks to 60 women, a dose the authors described as allowed by Thai and Taiwanese food and drug authorities.
Can glutathione be nebulized?
It can be put in a nebulizer, and a 1997 trial showed why that matters. Eight patients with mild asthma inhaled 600 milligrams, and their FEV1 fell 19 percent against 1 percent on placebo, with cough in four patients and breathlessness in three.
Does a higher glutathione dose work better?
No human study in this record tested one dose against another. The largest verified intravenous trial used a single dose and found no significant difference from placebo, so the claim that more glutathione produces more effect has no trial behind it.
Is oral glutathione safer than an injection?
The risks differ. Oral trials in healthy volunteers reported mild events and reversible liver enzyme rises in two participants, while the injection record includes hospital admissions tied to endotoxin in the powder. CDC’s guidance is to confirm the ingredient grade before any injectable dose.
What happens if a reaction starts after an injection?
Stop the infusion and get assessed. CDC lists fever, chills, muscle pain, nausea, vomiting, low blood pressure, a fast heart rate and injection-site reactions as signs to evaluate, and asks clinicians to report suspected events to FDA MedWatch.
Sources:
- CDC, Adverse Events Linked to Injectable Glutathione Compounded with Dietary Supplement Grade Ingredient: Current Situation, reviewed September 15, 2026.
- FDA, FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables, June 7, 2019.
- FDA, FDA reminds compounders not to use dietary supplement grade glutathione for injectables, August 27, 2026.
- FDA, Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, June 8, 2022, approved August 19, 2022.
- Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord, May 15, 2009.
- Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat, April 2012.
- Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol, April 27, 2017.
- Marrades RM, Roca J, Barberà JA, Jover L, MacNee W, Rodriguez-Roisin R. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. Am J Respir Crit Care Med, August 1997.
This article is information, not medical advice. Glutathione injections are compounded drugs with no FDA approval in the United States, and any decision about dose, route or suitability belongs to a licensed prescriber who knows your history. A reaction during or after an injection should go to a clinician and to FDA MedWatch.